MR blood pool agent approaches U.S. market

Article

In the coming months, Lantheus Medical Imaging plans to introduce an MR blood pool contrast agent to the U.S. market under the brand name Ablavar. From its booth on the RSNA exhibit floor, company staff will be available to discuss key points about the agent, which was originally developed by Epix Pharmaceuticals and branded under the name Vasovist.

In the coming months, Lantheus Medical Imaging plans to introduce an MR blood pool contrast agent to the U.S. market under the brand name Ablavar. From its booth on the RSNA exhibit floor, company staff will be available to discuss key points about the agent, which was originally developed by Epix Pharmaceuticals and branded under the name Vasovist. These points include Ablavar’s position as the first and only blood pool contrast agent approved for MR angiography to evaluate aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease; how its albumin-binding properties allow multiple images to be obtained using a single, low-dose injection; and its role in visualizing both arterial and venous blood vessels.  In April 2009, Lantheus acquired the U.S., Canadian, and Australian rights to the agent, technically called gadofosveset trisodium, which has been approved by the FDA for marketing as an aide in detecting aortoiliac occlusive disease.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.